Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and Leukemia Group B 30601): a brief report

INTRODUCTION: We conducted a phase II trial of dasatinib in malignant mesothelioma (MM) patients to evaluate its toxicity and efficacy as a second-line treatment. MATERIAL AND METHODS: Patients with unresectable MM and no symptomatic effusions were given dasatinib 70 mg twice daily as part of a 28-d...

Full description

Saved in:
Bibliographic Details
Main Authors: Dudek, Arkadiusz Z., Pang, Herbert, Kratzke, Robert A., Otterson, Gregory A., Hodgson, Lydia, Vokes, Everett E., Kindler, Hedy L.
Format: Artigo
Language:Inglês
Published: 2012
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3308128/
https://ncbi.nlm.nih.gov/pubmed/22425926
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e318248242c
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items